We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Watson Revises Generics Focus to Achieve $600 Million
Watson Revises Generics Focus to Achieve $600 Million
February 2, 2010
Watson Pharmaceuticals has realigned its sales force following its acquisition of Arrow Group to increase its focus on urology, obstetrics and gynecology treatment areas and certain primary care markets.